Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 2
1990 2
1991 4
1992 4
1993 5
1994 10
1995 19
1996 26
1997 59
1998 86
1999 59
2000 66
2001 37
2002 44
2003 25
2004 41
2005 38
2006 43
2007 32
2008 36
2009 36
2010 37
2011 30
2012 31
2013 31
2014 29
2015 25
2016 26
2017 26
2018 14
2019 10
2020 13
2021 20
2022 16
2023 12
2024 7
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

923 results

Results by year

Filters applied: . Clear all
Page 1
Mibefradil (posicor).
Giles TD. Giles TD. Compr Ther. 1997 Nov;23(11):761-3. Compr Ther. 1997. PMID: 9360806 Review. No abstract available.
Mibefradil: a selective T-type calcium antagonist.
Massie BM. Massie BM. Am J Cardiol. 1997 Nov 6;80(9A):23I-32I. doi: 10.1016/s0002-9149(97)00791-1. Am J Cardiol. 1997. PMID: 9375939 Review.
Mibefradil is the first of a new class of calcium antagonists with a unique structure and pharmacology. ...In animal studies, mibefradil increases coronary blood flow during induced ischemia. In addition, in vitro studies demonstrated that mibefradil decrease …
Mibefradil is the first of a new class of calcium antagonists with a unique structure and pharmacology. ...In animal studies, mibe …
Clinical pharmacokinetics of mibefradil.
Welker HA, Wiltshire H, Bullingham R. Welker HA, et al. Clin Pharmacokinet. 1998 Dec;35(6):405-23. doi: 10.2165/00003088-199835060-00001. Clin Pharmacokinet. 1998. PMID: 9884814 Review.
Mibefradil, a tetralol derivative, is a new long-acting calcium antagonist used for the treatment of patients with hypertension and chronic stable angina pectoris. ...Renal function does not affect the pharmacokinetics of mibefradil....
Mibefradil, a tetralol derivative, is a new long-acting calcium antagonist used for the treatment of patients with hypertension and c …
Mibefradil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of hypertension and angina pectoris.
Brogden RN, Markham A. Brogden RN, et al. Drugs. 1997 Nov;54(5):774-93. doi: 10.2165/00003495-199754050-00010. Drugs. 1997. PMID: 9360062 Review.
Mibefradil belongs to a new class of calcium antagonists, the tetralol derivatives. It selectively blocks T-type calcium channels in contrast to other calcium antagonists which block only L-type channels. Mibefradil relaxes coronary arteries without suppressing myoc …
Mibefradil belongs to a new class of calcium antagonists, the tetralol derivatives. It selectively blocks T-type calcium channels in …
Mibefradil, a T-type channel-selective calcium antagonist: clinical trials in chronic stable angina pectoris.
Massie BM. Massie BM. Am J Hypertens. 1998 Apr;11(4 Pt 3):95S-102S. doi: 10.1016/s0895-7061(98)00006-5. Am J Hypertens. 1998. PMID: 9607373 Review.
Mibefradil further improved exercise tolerance test duration and other efficacy parameters when administered concomitantly to patients on background beta-blocker or nitrate therapy. ...Mibefradil was safe and well tolerated in all studies....
Mibefradil further improved exercise tolerance test duration and other efficacy parameters when administered concomitantly to patient …
[Mibefradil improves skeletal muscle mass, function and structure in obese mice].
Wu J, Wu Y, Yang Y, Yu J, Fu R, Sun Y, Xiao Q. Wu J, et al. Nan Fang Yi Ke Da Xue Xue Bao. 2022 Jul 20;42(7):1032-1037. doi: 10.12122/j.issn.1673-4254.2022.07.10. Nan Fang Yi Ke Da Xue Xue Bao. 2022. PMID: 35869766 Free PMC article. Chinese.
OBJECTIVE: To observe the effect of mibefradil on skeletal muscle mass, function and structure in obese mice. METHODS: Fifteen 6-week-old C57BL/6 mice were randomized equally into normal diet group (control group), high-fat diet (HFD) group and high-fat diet +mibefradil …
OBJECTIVE: To observe the effect of mibefradil on skeletal muscle mass, function and structure in obese mice. METHODS: Fifteen 6-week …
Mibefradil, a T-type Ca(2+) channel blocker also blocks Orai channels by action at the extracellular surface.
Li P, Rubaiy HN, Chen GL, Hallett T, Zaibi N, Zeng B, Saurabh R, Xu SZ. Li P, et al. Br J Pharmacol. 2019 Oct;176(19):3845-3856. doi: 10.1111/bph.14788. Epub 2019 Aug 19. Br J Pharmacol. 2019. PMID: 31271653 Free PMC article.
BACKGROUND AND PURPOSE: Mibefradil, a T-type Ca(2+) channel blocker, has been investigated for treating solid tumours. ...Intracellular application of mibefradil did not alter Orai3 channel activity. Mibefradil at higher concentrations (>50 muM) inhibited …
BACKGROUND AND PURPOSE: Mibefradil, a T-type Ca(2+) channel blocker, has been investigated for treating solid tumours. ...Intracellul …
Mibefradil: the sole exception.
Weerasuriya K. Weerasuriya K. Lancet. 1998 Sep 5;352(9130):823-4. doi: 10.1016/S0140-6736(05)60724-6. Lancet. 1998. PMID: 9737324 No abstract available.
Mibefradil reduces blood glucose concentration in db/db mice.
Lu Y, Long M, Zhou S, Xu Z, Hu F, Li M. Lu Y, et al. Clinics (Sao Paulo). 2014 Jan;69(1):61-7. doi: 10.6061/clinics/2014(01)09. Clinics (Sao Paulo). 2014. PMID: 24473561 Free PMC article.
The hypoglycemic effect of mibefradil was reproduced by NNC 55-0396, a compound structurally similar to mibefradil but more selective for T-type Ca2+ channels, but not by the specific L-type Ca2+ channel blocker nicardipine. Mibefradil did not show such hypog …
The hypoglycemic effect of mibefradil was reproduced by NNC 55-0396, a compound structurally similar to mibefradil but more se …
Mibefradil represents a new class of benzimidazole TRPM7 channel agonists.
Schäfer S, Ferioli S, Hofmann T, Zierler S, Gudermann T, Chubanov V. Schäfer S, et al. Pflugers Arch. 2016 Apr;468(4):623-34. doi: 10.1007/s00424-015-1772-7. Epub 2015 Dec 16. Pflugers Arch. 2016. PMID: 26669310
Using Ca(2+) imaging and the patch-clamp technique, we show that mibefradil activates TRPM7-mediated Ca(2+) entry and whole-cell currents. The response to mibefradil was fast, reversible, and reproducible. ...Consequently, a TRPM7 variant harboring a gain-of-functio …
Using Ca(2+) imaging and the patch-clamp technique, we show that mibefradil activates TRPM7-mediated Ca(2+) entry and whole-cell curr …
923 results